C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 84 filers reported holding C4 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $461,749 | -27.3% | 248,252 | +7.5% | 0.00% | – |
| Q2 2023 | $635,344 | -36.2% | 231,034 | -27.1% | 0.00% | – |
| Q1 2023 | $995,408 | -52.7% | 317,009 | -11.1% | 0.00% | -100.0% |
| Q4 2022 | $2,104,247 | -31.9% | 356,652 | +1.3% | 0.00% | 0.0% |
| Q3 2022 | $3,089,000 | +50.0% | 352,125 | +28.9% | 0.00% | 0.0% |
| Q2 2022 | $2,060,000 | -68.9% | 273,189 | +0.0% | 0.00% | -50.0% |
| Q1 2022 | $6,627,000 | -22.2% | 273,137 | +3.2% | 0.00% | -33.3% |
| Q4 2021 | $8,522,000 | -26.8% | 264,651 | +1.6% | 0.00% | -25.0% |
| Q3 2021 | $11,637,000 | +118.7% | 260,452 | +85.3% | 0.00% | +100.0% |
| Q2 2021 | $5,321,000 | +106.3% | 140,594 | +101.7% | 0.00% | +100.0% |
| Q1 2021 | $2,579,000 | +16.6% | 69,712 | +4.4% | 0.00% | 0.0% |
| Q4 2020 | $2,212,000 | – | 66,742 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |